NCT00856869View on ClinicalTrials.gov

Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

February 28, 2005

Study Completion Date

April 30, 2005

Conditions
Hepatic CirrhosisNonalcoholic Steatohepatitis
Interventions
DRUG

NRL972

Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

DRUG

NRL972

Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

DRUG

NRL972

Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

DRUG

NRL972

Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

DRUG

NRL972

Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

DRUG

NRL972

Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

DRUG

NRL972

Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

Trial Locations (1)

1431

UMHAPT St. Ivan Rilski's University Hospital, Sofia

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY

NCT00856869 - Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers | Biotech Hunter | Biotech Hunter